Related Experiment Video
Updated: May 23, 2026

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays
Published on: June 13, 2019
Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML
Alyson A Lokken1, Nancy J Zeleznik-Le
1Oncology Institute, Loyola University Chicago, Maywood, IL 60153, USA.
Abstract:
KDM1A/LSD1, a histone H3K4/K9 demethylase and epigenetic regulator with roles in both gene activation and repression, has increased expression in multiple cancer types. Harris et al., in this issue of Cancer Cell, and Schenk et al. show that KDM1A may be a viable therapeutic target in treating AML.
More Related Videos
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
09:56Epigenetic Engineering of K562 Cells: Dual-Vector Episomal Strategy for Stable Targeted DNA Methylation using dCas9-DNMT3A and -HDAC1 Fusion Proteins
Published on: October 31, 2025